JP6472635B2 - コラーゲン水溶液及びそれを用いたゲルの製造方法 - Google Patents
コラーゲン水溶液及びそれを用いたゲルの製造方法 Download PDFInfo
- Publication number
- JP6472635B2 JP6472635B2 JP2014210057A JP2014210057A JP6472635B2 JP 6472635 B2 JP6472635 B2 JP 6472635B2 JP 2014210057 A JP2014210057 A JP 2014210057A JP 2014210057 A JP2014210057 A JP 2014210057A JP 6472635 B2 JP6472635 B2 JP 6472635B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- aqueous solution
- solution
- collagen aqueous
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008186 Collagen Human genes 0.000 title claims description 147
- 108010035532 Collagen Proteins 0.000 title claims description 147
- 229920001436 collagen Polymers 0.000 title claims description 147
- 239000007864 aqueous solution Substances 0.000 title claims description 68
- 238000004519 manufacturing process Methods 0.000 title description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 11
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 10
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 9
- 235000019800 disodium phosphate Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 24
- 206010016654 Fibrosis Diseases 0.000 description 20
- 230000004761 fibrosis Effects 0.000 description 20
- 230000036760 body temperature Effects 0.000 description 19
- 239000000499 gel Substances 0.000 description 18
- 238000003860 storage Methods 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 238000005259 measurement Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 229910017053 inorganic salt Inorganic materials 0.000 description 12
- 230000004043 responsiveness Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 238000001879 gelation Methods 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 5
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 4
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 4
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010061592 cardiac fibrillation Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000512 collagen gel Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 240000001972 Gardenia jasminoides Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000003352 fibrogenic effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LMPDLIQFRXLCMO-UHFFFAOYSA-L dipotassium;hydrogen phosphate;phosphoric acid Chemical compound [K+].[K+].OP(O)(O)=O.OP([O-])([O-])=O LMPDLIQFRXLCMO-UHFFFAOYSA-L 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Description
[1]コラーゲンと水とを含むコラーゲン水溶液であって、23℃におけるpHが6.0〜9.0であり、ナトリウム塩のイオン強度が0.60〜1.2であり、かつ、コラーゲン濃度が0.50%〜2.5%である、コラーゲン水溶液。
[2]リン酸水素ナトリウム及び塩化ナトリウムを含む、上記のコラーゲン水溶液。
[3]前記コラーゲンは、哺乳類由来テロペプチド除去型コラーゲンを含む、上記のコラーゲン水溶液。
〔コラーゲン原液の準備〕
濃度1.0質量%のブタ皮膚製コラーゲン溶液(テロペプチド除去型コラーゲン、日本ハム株式会社製、コラーゲンの変性温度:40℃)をコラーゲン原液として準備した。エバポレーター(水溶温度29℃)を用いてコラーゲン原液を濃縮し、濃度2.4%のコラーゲン溶液を得た。最終的に得られるコラーゲン水溶液のコラーゲン濃度が表1に示す数値になるように、適宜希塩酸(pH=3)をその溶液に添加した。
上記のようにして準備したコラーゲン溶液を、15mL遠心チューブに6gずつ入れ、庫内温度を4℃に調整した冷蔵庫内に静置した。上記のようにして冷蔵庫内に静置したコラーゲン溶液に、pH及びイオン強度が表1に示す数値になるよう予め調製した所定濃度(表1参照。)のリン酸ナトリウム及び塩化ナトリウムを含むリン酸緩衝液を添加し、手による転倒撹拌とボルテックスミキサーによる撹拌とを繰り返し、およそ20秒間で撹拌を終えて、コラーゲン水溶液を得た。コラーゲン水溶液の23℃におけるpHを、pHメータ(HORIBA社製、型式F−51)により測定した結果を表1に示す。また、コラーゲン水溶液のイオン強度の算出値を表1に示す。なお、本実施例では、コラーゲン水溶液のpHが7.0である場合のみの結果を示すが、コラーゲンの線維化のpH依存性は、従来知られているものと同程度であった。
上記のようにして得たコラーゲン水溶液について、動的粘弾性測定を行った。動的粘弾性測定装置として、サーモフィッシャーサイエンティフィック社製の商品名「HAAKE MARS III」を用いて、コラーゲン水溶液の動的粘弾性測定(微小振動モード)を行った。ジオメトリ及び測定プログラムは実験目的に応じて使い分けた。以下に測定条件を示す。
実施例1〜5及び比較例1〜6のコラーゲン水溶液の調製後、4分30秒以内にサンプルをセットし、まず120秒経過の間、23℃にて保持した後、30秒間に37度まで昇温し、60秒間その温度で一定に保持したときの貯蔵弾性率を測定した。測定条件は下記のとおりであった。
ジオメトリ:パラレルセンサー(内径60mm)
測定プロファイル:CD(Controlled Deformation)モードによるオシレーション測定において、温度を変化させた(せん断歪み=0.005、温度=23→37℃、周波数=1Hz、プレート間のギャップ=1mm)。測定開始後、貯蔵弾性率G'の時間変化を追跡した。
実施例1〜3及び比較例1のコラーゲン水溶液の調製後、4分30秒以内にサンプルをセットし、23℃にて30分間保持した後、測定を開始した。測定条件は下記のとおりであった。
ジオメトリ:パラレルセンサー(内径60mm)
測定プロファイル:CD(Controlled Deformation)モードによるオシレーション測定(せん断歪み=0.005、温度=23℃、周波数=1Hz、プレート間のギャップ=1mm)とした。測定開始後、貯蔵弾性率G'の時間変化を追跡した。
結果を図3に示す。
Claims (3)
- コラーゲンと水とを含むコラーゲン水溶液であって、23℃におけるpHが6.0〜9.0であり、ナトリウム塩のイオン強度が0.60〜1.2であり、かつ、コラーゲン濃度が0.50%〜2.5%である、コラーゲン水溶液。
- リン酸水素ナトリウム及び塩化ナトリウムを含む、請求項1記載のコラーゲン水溶液。
- 前記コラーゲンは、哺乳類由来テロペプチド除去型コラーゲンを含む、請求項1又は2に記載のコラーゲン水溶液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014210057A JP6472635B2 (ja) | 2014-10-14 | 2014-10-14 | コラーゲン水溶液及びそれを用いたゲルの製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014210057A JP6472635B2 (ja) | 2014-10-14 | 2014-10-14 | コラーゲン水溶液及びそれを用いたゲルの製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016077410A JP2016077410A (ja) | 2016-05-16 |
JP6472635B2 true JP6472635B2 (ja) | 2019-02-20 |
Family
ID=55956736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014210057A Active JP6472635B2 (ja) | 2014-10-14 | 2014-10-14 | コラーゲン水溶液及びそれを用いたゲルの製造方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6472635B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190084286A (ko) * | 2016-11-17 | 2019-07-16 | 지호우도쿠리츠교우세이호우징 도쿄토리츠 산교기주츠켄큐센타 | 생체 조직 구멍 폐쇄용, 궤양 보호용 및 혈관 색전 치료술용 졸 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7007086B2 (ja) | 2016-11-17 | 2022-01-24 | 地方独立行政法人東京都立産業技術研究センター | 粘膜下局注用コラーゲンゾル |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5869806A (ja) * | 1981-10-20 | 1983-04-26 | Mochida Pharmaceut Co Ltd | 安定なコラ−ゲン含有化粧用ロ−シヨン |
JP2009148275A (ja) * | 2000-08-30 | 2009-07-09 | Morisuke Yokoyama | 特定保健用食品 |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
JP2009268685A (ja) * | 2008-05-07 | 2009-11-19 | Hoya Corp | アパタイト/コラーゲン複合体で被覆してなる人工骨、及びその製造方法 |
JP5789927B2 (ja) * | 2010-07-30 | 2015-10-07 | Jnc株式会社 | 放射線照射コラーゲン様ペプチドを用いた核酸導入法 |
-
2014
- 2014-10-14 JP JP2014210057A patent/JP6472635B2/ja active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190084286A (ko) * | 2016-11-17 | 2019-07-16 | 지호우도쿠리츠교우세이호우징 도쿄토리츠 산교기주츠켄큐센타 | 생체 조직 구멍 폐쇄용, 궤양 보호용 및 혈관 색전 치료술용 졸 |
KR102408275B1 (ko) | 2016-11-17 | 2022-06-10 | 지호우도쿠리츠교우세이호우징 도쿄토리츠 산교기주츠켄큐센타 | 생체 조직 구멍 폐쇄용, 궤양 보호용 및 혈관 색전 치료술용 졸 |
Also Published As
Publication number | Publication date |
---|---|
JP2016077410A (ja) | 2016-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6380154B1 (en) | Synthetic proteins for in vivo drug delivery and tissue augmentation | |
KR102223440B1 (ko) | 세포외 기질 재료로부터의 생리활성 겔의 제조 방법 | |
JP2020055836A (ja) | 自己組織化ペプチド組成物 | |
JP6071468B2 (ja) | コラーゲン水溶液及びそれから得られるゲル | |
Tan et al. | Enlisting a Traditional Chinese Medicine to tune the gelation kinetics of a bioactive tissue adhesive for fast hemostasis or minimally invasive therapy | |
WO2014005471A1 (zh) | 一种温敏型可注射壳聚糖水凝胶产品及其应用 | |
CN105504316B (zh) | 一种透明质酸‑甲基纤维素复合凝胶的活性酯交联方法 | |
US11179494B2 (en) | Collagenous tissue repair device | |
CN103333508A (zh) | 一种注射用胶原蛋白水凝胶及其制备方法 | |
CN107660146B (zh) | pH接近生理pH的可注射的均相壳聚糖水溶液 | |
US20110275572A1 (en) | Nanocomposite Hyaluronic Acid-Clay Based Hydrogels | |
Zheng et al. | A dual crosslinked hydrogel-mediated integrated peptides and BMSC therapy for myocardial regeneration | |
WO2018092837A1 (ja) | 粘膜下局注用コラーゲンゾル | |
JP6472635B2 (ja) | コラーゲン水溶液及びそれを用いたゲルの製造方法 | |
US20140005306A1 (en) | Hyaluronic Acid-Gelatin Crosslinked Thermoreversible Pluronic Hydrogels | |
JP2016077411A (ja) | コラーゲンゲルの作製方法及びコラーゲンゲル | |
JP5944902B2 (ja) | 機能性ハイドロゲル | |
US20200060959A1 (en) | Method for preparing an aqueous hyaluronic acid gel | |
CN111249172A (zh) | 一种美容注射凝胶及其制备方法 | |
CN115887742A (zh) | 抗菌功能性胶原基可注射自修复水凝胶的制备方法 | |
CN110215542A (zh) | 一种形成血管临时阻塞物的方法 | |
CN104083320B (zh) | 可注射型载药黄原胶/甲基纤维素复合溶液及其制备方法 | |
JP6432967B2 (ja) | 溶解性コラーゲン線維多孔体 | |
JP2017502043A (ja) | キシログルカンゲル中のfgf−18製剤 | |
WO2021066078A1 (ja) | 筋組織再生剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180913 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190123 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6472635 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |